New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Unlock Exclusive Insights: Sign Up and Stay Informed

Love staying informed? Our newsletter brings the latest and greatest straight to your inbox. No spam, just good reads. Sign up and let’s stay in touch!